BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 9665342)

  • 1. Degradation of urokinase plasminogen activator (UPA) in endometrial stromal cells requires both the UPA receptor and the low-density lipoprotein receptor-related protein/alpha2-macroglobulin receptor.
    Casslén B; Gustavsson B; Angelin B; Gåfvels M
    Mol Hum Reprod; 1998 Jun; 4(6):585-93. PubMed ID: 9665342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
    J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
    Nykjaer A; Petersen CM; Møller B; Jensen PH; Moestrup SK; Holtet TL; Etzerodt M; Thøgersen HC; Munch M; Andreasen PA
    J Biol Chem; 1992 Jul; 267(21):14543-6. PubMed ID: 1378833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex.
    Stefansson S; Kounnas MZ; Henkin J; Mallampalli RK; Chappell DA; Strickland DK; Argraves WS
    J Cell Sci; 1995 Jun; 108 ( Pt 6)():2361-8. PubMed ID: 7673355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor.
    Conese M; Nykjaer A; Petersen CM; Cremona O; Pardi R; Andreasen PA; Gliemann J; Christensen EI; Blasi F
    J Cell Biol; 1995 Dec; 131(6 Pt 1):1609-22. PubMed ID: 8522616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor.
    Casslén B; Nordengren J; Gustavsson B; Nilbert M; Lund LR
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2776-84. PubMed ID: 7673423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
    Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
    Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide.
    Zhang L; Strickland DK; Cines DB; Higazi AA
    J Biol Chem; 1997 Oct; 272(43):27053-7. PubMed ID: 9341144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both pro-uPA and uPA: PAI-1 complex bind to the alpha 2-macroglobulin receptor/LDL receptor-related protein. Evidence for multiple independent contacts between the ligands and receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Gliemann J; Andreasen PA
    Ann N Y Acad Sci; 1994 Sep; 737():483-5. PubMed ID: 7944152
    [No Abstract]   [Full Text] [Related]  

  • 12. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
    Sitter T; Toet K; Quax P; Kooistra T
    Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and alpha2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein.
    Kasza A; Petersen HH; Heegaard CW; Oka K; Christensen A; Dubin A; Chan L; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(2):270-81. PubMed ID: 9346278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocytosis of urokinase-plasminogen activator inhibitor type 1 complexes bound to a chimeric transmembrane urokinase receptor.
    Li H; Kuo A; Kochan J; Strickland D; Kariko K; Barnathan ES; Cines DB
    J Biol Chem; 1994 Mar; 269(11):8153-8. PubMed ID: 7510679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
    Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
    Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of pro-urokinase.
    Kounnas MZ; Henkin J; Argraves WS; Strickland DK
    J Biol Chem; 1993 Oct; 268(29):21862-7. PubMed ID: 7691818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor.
    Conese M; Olson D; Blasi F
    J Biol Chem; 1994 Jul; 269(27):17886-92. PubMed ID: 8027043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal release of urokinase plasminogen activator, plasminogen activator inhibitor-1, and soluble plasminogen activator receptor from separated and cultured endometriotic and endometrial stromal and epithelial cells.
    Bruse C; Guan Y; Carlberg M; Carlström K; Bergqvist A
    Fertil Steril; 2005 Apr; 83 Suppl 1():1155-60. PubMed ID: 15831288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
    Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
    Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
    Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.